Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNAseq of A375 cells treated with Panobinostat

ABSTRACT: Bulk RNAseq of A375 cells treated with Panobinostat

PROVIDER: PRJNA607239 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11100432.fastq.gz	Fastqsanger.gz
	SRR11100433.fastq.gz	Fastqsanger.gz
	SRR11100434.fastq.gz	Fastqsanger.gz
	SRR11100435.fastq.gz	Fastqsanger.gz
	SRR11100436.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Bulk RNAseq of A375 cells treated with Panobinostat

Project description:The MICA and MICB genes are epigenetically regulated by HDACs. We tested if panobinostat, a broad spectrum HDAC inhibitor, affects the expression of MICA and MICB gene by a human melanoma cell line.

2020-02-19 | GSE145447 | GEO

RNAseq to investigate transcriptional changes in human MM cell lines due to panobinostat, 5-Azacytidine, panobinostat+5-Azacytidine or n-methyl-2-pyrroldine (NMP) treatments.

Project description:Purpose: We applied RNA sequencing technology for high-throughput analysis of transcriptional changes within human MM cell lines JJN3 and U266 due to individual and combination drug treatment. Methods: JJN3 and U266 cells were treated with pan-HDACi panbobinostat, DNMTi 5-Azacytidine, panobinostat+5-Azacytidine or NMP for 4h or 24h in triplicate and transcriptional changes assessed by RNAseq using Illumina HiSeq platform. Specifically, JJN3 cells were treated with 10nM panobinostat, 2.5µM 5-Azacytidine, panobinostat+5-Azacytidine (at given doses), or 10mM NMP. U266 cells were treated with 10nM panobinostat, 10µM 5-Azacytidine, panobinostat+5-Azacytidine (at given doses), or 10mM NMP. Results: We report unique and overlapping transcriptional signatures that lead to the induction of apoptosis in human MM cell lines in a cell-specific manner due to individual or combination treatments. Conclusions: A detailed analysis of differential transcriptional events in human MM cell lines due to HDACi, DNMTi, HDACi+DNMTi and NMP appear to define the molecular events leading to apoptosis and drug mechanism of action. We tested triplicate experiments at 4h and 24hr time points in JJN3 and U266 cell lines against vehicle control treated cells.

2014-04-09 | E-GEOD-56623 | biostudies-arrayexpress

RNAseq to investigate transcriptional changes in human MM cell lines due to panobinostat, 5-Azacytidine, panobinostat+5-Azacytidine or n-methyl-2-pyrroldine (NMP) treatments.

2014-04-09 | GSE56623 | GEO

Myc-driven medulloblastoma cells treated with Panobinostat (LBH589)

Project description:Mouse MycT58A/DNp53 (MP) medulloblastoma cells were treated with DMSO or HDAC inhibitor (HDACi) panobinostat for 6 or 12 hours in vitro. Gene expression profiling was performed to compare cells treated with panobinostat and DMSO.

2015-06-02 | GSE69410 | GEO

A375 melanoma cells treated with leflunomide 25uM

Project description:Human A375 melanoma cells were treated with leflunomide 25uM for 3 days, then RNA harvested

2011-03-30 | GSE24526 | GEO

Differential gene expression in neuroblastoma cells after treatment with vehicle control, JQ1, panobinostat, or combination of JQ1 and panobinostat

Project description:The bromodomain inhibitor JQ1 and the histone deacetylase inhibitor panobinostat induce synergistic anticancer effects We analyzed whether JQ1 and panobinostat synergistically modulate gene expression Neuroblastoma SK-N-BE(2) cells were treated with vehicle control, 1 microM JQ1, 10 nM panobinostat, or combination of JQ1 and panobinostat for 6 hours, and subjected to differential gene expression studies with Affymetrix microarrays.

2015-12-31 | E-GEOD-68690 | biostudies-arrayexpress

Bulk RNAseq of HDLECs [ctl vs ITGB3 siRNA]

Project description:Bulk RNAseq was performed using control or ITGB3 siRNA treated human dermal lymphatic endothelial cells (HDLECs)

2023-06-01 | GSE224655 | GEO

U937 treated with decitabine, panobinostat and valproic acid

Project description:U937 treated with decitabine, panobinostat and valproic acid

| PRJNA321257 | ENA

Human A375 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59340 | GEO

Bulk RNAseq of HUVECs

Project description:Bulk RNAseq of HUVECs

| PRJNA862721 | ENA